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A sthma affects 15-20 million individuals in the United States and costs Ͼ$15 billion/year to treat. 1 Updated guidelines from The National Heart, Lung, and Blood Institute focus on improving control of asthma symptoms through the stepwise use of prescription medications. 2 The Joint Council of Allergy, Asthma, and Immunology Practice Parameters Task Force published a practice parameter that also emphasized the importance of achieving control of asthma symptoms, in part through appropriate prescribing of "controller" medications. 3 Other aspects of asthma management that can encourage well-controlled asthma include adherence with avoidance measures and appropriate treatment of comorbid conditions (e.g., chronic sinusitis and gastroesophageal reflux). Asthma control includes two components: impairment and future risk. Impairment comprises the frequency and intensity of symptoms and patients' current or recent physical limitations. Risk comprises potential for asthma exacerbations, decline in lung development or function, and medication-related adverse events. 2 The implication of this focus on medication use to improve control is that if patients adhere to their treatment regimens, most will be able to control their symptoms. Because up to one-half of patients who are receiving long-term asthma treatment do not take medications appropriately, improving adherence has been the focus of many studies. 4 -7 However, several investigators have shown that adherence to treatment may not completely prevent exacerbations. 8 -10 Little is known about the level of asthma control achieved by adherent patients outside the highly controlled setting of clinical trials. In this study, administrative claims were used to investigate the extent of asthma control achieved in practice among patients treated with high-dose combination inhaled corticosteroid (ICS)/ long-acting ␤-agonist (LABA) inhalers who had varying
Patient Selection
Identified patients were 12-64 years old and were newly treated with fluticasone, 500 g/salmeterol, 50 g, during a 18-month identification period (January 1, 2003, through June 30, 2004) . This was the only combination ICS/LABA inhaler marketed in the United States during the study. New use of fluticasone, 500 g/salmeterol, 50 g, served to identify a group with somewhat similar disease severity because at that dosage it is used to treat moderate-to-severe persistent asthma. 2, 11 For the same reason, patients who were receiving high-dose combination therapy had to have evidence of controller use in the year before the index date. That is, we excluded those whose first identified controller was high-dose combination therapy because these patients may have differed systematically in their disease severity from our target population.
Other methods of identifying moderate-to-severe asthma patients required clinical data not in the database or were confounded by the outcomes of interest (use of services and additional controller medications). The date of the first claim for fluticasone, 500 g/ salmeterol, 50 g, during this period was the index date, and the year following this date was defined as the study year. Patients who had any pharmacy claims for this dosage during the year before the index date were excluded. Patients had to be enrolled in their health plans continuously for 1 year before and 1 year after the index date.
Asthma diagnosis was confirmed by one or more medical claims with an International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) code for asthma (493.xx) and at least one preindex claim for an asthma controller medication other than fluticasone, 500 g/salmeterol, 50 g (e.g., ICSs, LABA inhalers, and leukotriene receptor antagonists [LTRAs] ). Medications were identified using National Drug Codes. Patients were excluded if they had any claims with ICD-9-CM codes for chronic obstructive pulmonary disease (491.xx, 492.xx, or 496.xx) or if they had claims with a National Drug Code or Health Care Common Procedure Coding System J code 12 for omalizumab, because patients who used this medication may have had more severe disease.
Descriptive Variables
Baseline variables (measured in the preindex year) included demographic characteristics, asthma medication use, and asthma-related medical use. There were no indicators of socioeconomic status or race/ethnicity available. To describe concomitant controller medication use, we used six nonexclusive categories: fluticasone, 250 g/salmeterol, 50 g; fluticasone, 100 g/ salmeterol, 50 g; ICSs plus LABAs as separate inhalers; ICSs plus LTRAs; ICSs only; and other controller medications (LTRAs or LABAs alone or in combination, but without ICSs or fluticasone/salmeterol).
Outcome and Stratification Variables
The main outcome measure was poor disease control in the postindex year, defined as one or more claims for emergency department (ED) visits or hospitalizations where asthma was the first diagnosis, six or more pharmacy claims for short-acting ␤-agonists (SABAs), or two or more pharmacy claims for oral corticosteroids (OCSs). These outcomes have been used in a variety of studies as markers of poor control and correlate with patient-centered measures of disease. [13] [14] [15] [16] [17] Clinical indicators of disease severity or control such as decreased peak expiratory flow rate or forced expiratory volume in 1 second were not available.
Patients were grouped according to fluticasone, 500 g/salmeterol, 50 g, adherence levels in the postindex year. Using a published approach, the "days' supply" was used to determine adherence. 18 Total therapy days for each patient were determined by summing the days' supply for all fluticasone, 500 g/salmeterol, 50 g, fills, truncating fills beyond the end of the study year. Adherence was calculated as the percentage of total therapy days divided by 365. For example, if the sum of the days' supply for all fluticasone, 500 g/ salmeterol, 50 g, fills was 365 and the time frame of interest was 365 days, adherence equaled 100%. Each patient's adherence was categorized using the designations low (Ͻ50%), moderate (50 -74%), and high (Ն75%). For permission to copy go to www.copyright.com
Analysis
We reported descriptive statistics for baseline characteristics and compared the proportion of patients with poor control in each of the adherence cohorts. A subset of patients used controller medications other than fluticasone/salmeterol during the postindex period, which may have affected disease control. We reported proportions of patients with poor control among the subset who used additional controllers and stratified these by adherence. For continuous variables, values are presented as means with standard deviations (SDs). For categorical variables, numbers of patients with metrics of interest are accompanied by percentages. To compare outcomes between the adherence groups, Pearson's chi-squared test was used for categorical variables and the F test was used for continuous variables.
Patient characteristics differed across cohorts, so a logistic regression model was used to adjust for baseline differences. The model adjusted for the following variables from the preindex period: age (as a continuous variable) and gender, any asthma-related ED visit, any asthma-related hospitalization, two or more OCS fills, and six or more SABA fills (as dichotomous variables). Adjusted odds ratios (ORs) and 95% confidence intervals (CIs) were reported for logistic regression results. All reported p values are two-sided with a 0.05 significance level. All data transformations and statistical analyses were done using SAS Version 9.1 (SAS Institute, Cary, NC).
RESULTS
We identified 17,405 patients treated with high-dose fluticasone/salmeterol. After excluding those with chronic obstructive pulmonary disease, users of omalizumab, and those without continuous enrollment during the study year and the prior year, we had 6959 patients. We further excluded 2492 patients who were continuing, rather than new, users of fluticasone, 500 g/salmeterol, 50 g, and 578 patients who were not 12-65 years old. An additional 1110 patients had not used asthma controller medications in the year before beginning high-dose combination therapy and were excluded, leaving 3357 patients in the final study group (Fig. 1) .
Study patients had a mean age of 40.5 Ϯ 13.6 years and 64.1% were women (n ϭ 2151). Patients used a variety of medication regimens before starting fluticasone, 500 g/salmeterol, 50 g. The most common were fluticasone, 250 g/salmeterol, 50 g, used by 50.3% (n ϭ 1688), and ICSs alone, used by 14.0% (n ϭ 470). During the preindex period, 37.1% (n ϭ 1245) had poor disease control. Sixteen percent (n ϭ 536) had two or more OCS fills, 13.5% (n ϭ 453) had six or more SABA fills, 12.4% (n ϭ 416) had an asthma-related ED visit, and 8.2% (n ϭ 274) had an asthma-related hospitalization (Table 1) .
During the preindex period, 60.5% (n ϭ 2030) of patients had low adherence, 20.3% (n ϭ 682) had moderate adherence, and 19.2% (n ϭ 645) had high adherence. The low-adherence group had a mean age of 38.8 years, the moderate-adherence group had a mean age of 42.3 years, and the high-adherence group had a mean age of 44.0 years. A higher proportion of patients in the low-adherence group were women, and more patients in the low-adherence group used ICSs only before initiating combination therapy. Evidence of poor control in the preindex year was highest in the moderate-adherence group (Table 1) .
Before adjustment for baseline differences, 29.6% of patients (994/3357) met at least one criterion for poor control in the postindex period, compared with 37.1% (n ϭ 1245) in the preindex period, an absolute decrease of 7.5% (p Ͻ 0.0001; not shown). In an unadjusted analysis, an equal number of patients in all adherence cohorts had some evidence of poor control (Table 2) . Highly adherent patients had fewer asthma-related hospitalizations than the other two groups (p ϭ 0.004). The other components of poor control were similar across groups.
A subgroup of patients in each adherence group used additional controller medications besides highdose fluticasone/salmeterol. In the high-adherence group, 63.1% used LTRAs, 44.0% used ICSs, and was consistent across all adherence groups: about one-third of all patients who used additional controller medications had at least one indicator of poor control (Table 3) . There were baseline differences between adherence cohorts, so a logistic regression model was used to adjust for age, gender, and preindex evidence of poor control (asthma-related ED visits and hospitalizations, six or more SABA fills, and two or more OCS fills). Adjusted results were consistent with unadjusted ones. The OR for any evidence of poor control was 1.0 for the comparison of the low-to high-adherence group (95% CI, 0.8, 1.2) and for the comparison of the moderate to high group (95% CI, 0.8, 1.3). For each comparison, the lower adherence group had twice the odds of an asthma-related hospitalization as the higher group (Table 4).
DISCUSSION
The burden of asthma on affected individuals and society is enormous and rightly commands the attention of health professionals and policy makers. 20 -26 Despite clinical care guidelines for asthma, many patients' asthma remains poorly controlled and adverse outcomes are common. This study showed that nearly one-third of asthma patients highly adherent to highdose fluticasone/salmeterol therapy still had evidence of poor control. Even among the subset of highly adherent patients who used additional controller medication, rates of poor control were high.
Outcomes differed across adherence groups, with higher hospitalization rates for asthma in both adjusted and unadjusted analyses for patients who were not highly adherent to their medication. Use of controller medications has been shown to reduce use of health care services 27, 28 ; however, our study showed that poor control, as reflected in overreliance on "reliever" medications (SABAs and/or OCSs), is not infrequent in patients receiving combination controller therapy (including high-dose ICSs) despite patterns of medication adherence.
We found no other studies in a typical care setting examining rates of poor control among adherent patients, but adherence is usually high in randomized controlled trials (RCTs), and RCTs have shown rates of poor control similar to ours. One such study compared the efficacy of fluticasone propionate and salmeterol/ fluticasone in achieving totally and well-controlled asthma. 8 Among 3421 uncontrolled asthma patients studied, treatment was stepped up until total control was achieved or until the patient was receiving the maximum 1000-g/day dose of corticosteroids. At the conclusion of the 1-year trial, 41% of patients in one group and 29% in the other still did not have wellcontrolled asthma.
Findings were similar in an RCT of combination therapy with budesonide/formoterol, where 48 -57% of the patients still had at least one asthma exacerbation during a 12-week period despite up to 90 days of treatment. 9 The continued evidence of poor control despite adherence to treatment does not appear to be restricted to patients with moderate-to-severe asthma. In a trial of a variety of treatment regimens for patients with mild persistent asthma, adherence was 90 -100%, but after 16 weeks of therapy as many as one-third of patients had at least one indicator of poor control. 8 There are many reasons why highly adherent patients may not experience complete control. Therapy may be prescribed at inadequate doses, and adherence with an inappropriate regimen should not be expected to control disease. Medications may be given with poor instructions, or patients may not understand proper use (leading to poor technique or inappropriate use).
11
It is also possible that the highly adherent patients we studied who were treated with high-dose combination therapy actually needed more aggressive treatment with additional medications or other nonmedication interventions.
Despite optimal medication adherence, poor control may persist because of a variety of factors including (but not limited to) lack of aeroallergen avoidance, presence of comorbid conditions or psychosocial issues, or an erroneous diagnosis of asthma. 3 The current findings provide further support for the The National Heart, Lung, and Blood Institute guideline, which suggests that asthma patients, even highly adherent ones, should be aggressively managed if they show evidence of poor control.
Our study examined a large population in a naturalistic setting; we used logistic regression to control for baseline differences among groups, but the study had limitations. One definition of adherence is "the extent to which … behavior … corresponds with … recommendations from a health care provider," 29 and claims data provide no direct evidence of physicians' recommendations. We used the approach of measuring days of medication supplied as a proxy for prescription information. If a patient filled their prescription but did not use their medication, they would be counted as adherent. It would be difficult for patients to be more adherent than was estimated in this study (they would have to purchase medication without requesting reimbursement or use medication samples frequently). There is no reason to suspect that these behaviors would occur at different rates among the various adherence groups. Studies have found that although prescription claims are imperfect, they generally reflect actual medication use 30 -32 and are adequate for computing adherence. For permission to copy go to www.copyright.com severity. To reduce the effect of varying severity levels on our findings, we focused on new users of high-dose combination therapy and, specifically, those for whom this high-dose therapy was not the first controller used. We controlled for evidence of poor disease control at baseline. We could not measure severity directly, and if more severely affected patients adhered more closely with therapy, the association of adherence with control could have been confounded. According to a recent comprehensive review, the evidence that adherence varies with illness severity is limited. 34 Other problems inherent to automated claims data may have affected our findings. We were not able to measure drug sampling, which may have led to misclassification bias with respect to categorizing patients as having low rates of adherence and/or having low rates of reliance on SABAs. Coding errors may also have affected data integrity. Our study examined patients with commercial insurance and excluded children Ͻ12 years of age and adults Ͼ65 years of age. Our findings, therefore, may not reflect patterns of care among the uninsured, those with Medicaid or Medicare, or those receiving care in the Department of Veterans.
CONCLUSION
In a claims analysis, nearly one-third of asthma patients who were highly adherent to high-dose combination ICS/LABA therapy still had evidence of poor control, as measured by the need for hospitalization or ED utilization and/or the more frequent requirement for the use of "reliever" medications (SABAs and/or OCSs). Even among those highly adherent patients who used additional controller medication, rates of poor control were high. Patients with asthma, even highly adherent ones, should be aggressively managed if they show evidence of poor control. 
